Here’s why the Rhythm Biosciences (ASX:RHY) share price soared 8% today

Shares in the healthcare company surged after the company released a quarterly update.

| More on:
Lab worker puts hands in the air and dances around

Image source: Getty Images

Key points

  • The Rhythm Biosciences share price finished the day up by more than 8% after earlier jumping by 19%
  • The diagnostics company released its latest quarterly results today
  • Its colorectal cancer detection product, ColoSTAT, is set to gain EU and UK commercial exposure

The Rhythm Biosciences Ltd (ASX: RHY) share price surged today following the company’s latest quarterly activity update.

Among the business results, the diagnostic technology company released an update on its core product, ColoSTAT — a low-cost blood test used for the detection of colorectal cancer.

At the close of trading, the Rhythm Biosciences share price was up 8.43% at $1.35. During intra-day trade, it hit a high of $1.49, a gain of 19.2% on its previous closing price.

Let’s dive in and dissect this update…

What did Rhythm Biosciences report?

The Rhythm Biosciences share price jumped into the green after the company reported a total of $5.5 million cash in the bank for the period ending 31 December 2021. (This excluded a placement of $6.5 million before costs which was completed this month).

Secondly, it received a rebate of $2.4 million from its R&D Tax Incentive claim, in which the Australian government “encourages companies to engage in R&D programs by providing a refundable tax offset of up to 43.5% on eligible activities”.

Thirdly, it made three executive and non-executive enrolments to its board, including CEO Glenn Gilbert additionally taking on the role of managing director.

But probably most notable for the healthcare company was the progressing commercialisation of its product — the ColoSTAT.

ColoSTAT EU exposure

Rhythm Biosciences’ ColoSTAT product was recently granted a “CE Mark”. This means it has met all provisions of EU legislation required to be sold within the European Economic Area (EEA).

According to Listcorp, colorectal cancer — which the ColoSTAT aims to detect — is the third most common form of cancer for men, and second for women.

This certification exposes the company to 231 million people and a market valued at US$12 billion.

And since the quarter, its CE Mark certification now encapsulates England, Wales, Scotland, and Northern Ireland.

While the company is continuing to test its product to ensure “highly accurate, consistent and reproducible results” — at 84% sensitivity and 95% specificity — it has confirmed the product “significantly outperforms the current market testing regime, by as much as 33%”.

The company is therefore confident it will perform well in the market.

Looking forward, Rhythm Biosciences has employed a “platform expansion program”, using similar technology of ColoSTAT to diagnose other types of cancers.

Breast, cervical, lung, gastric, and pancreatic cancers are to be targeted for similar commercial pathways.

Rhythm Biosciences share price snapshot

The Rhythm Biosciences share price has jumped by 48% in the last six months. However, it is down around 12% this year to date.

The company has a market capitalisation of $265.99 million and over 213 million shares outstanding.

Should you invest $1,000 in Rhythm Biosciences right now?

Before you consider Rhythm Biosciences, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Rhythm Biosciences wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

Motley Fool contributor Alice de Bruin has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Growth Shares

Why CSL shares are ‘going to deliver’ in 2022: fund manager

Quality growth companies can perform well even in an era of rising interest rates.

Read more »

a group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Incannex share price pops 9% on FDA news

The medicinal cannabis drug development company came out with some positive developments from its FDA meeting...

Read more »

Two medical researchers in white coats collaborate over a computer screen of data in a medical research laboratory
Broker Notes

Where next for the CSL share price?

CSL shares could be heading higher according to one leading broker...

Read more »

A telehealth doctor at her desk.
Healthcare Shares

Why is the Ramsay share price smashing the ASX 200 on Monday?

Ramsay shares are off to a positive start today.

Read more »

a doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

What’s going on with the Polynovo share price today?

The strong start has dissipated for Polynovo shares.

Read more »

a doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Virtus share price holds steady despite 30% earnings fall

Shareholders are staying loyal with a looming acquisition.

Read more »

a medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Earnings Results

Avita Medical share price tumbles 7% on declining Q1 revenue

The ASX healthcare share saw its net loss for the quarter increase 58% year-on-year.

Read more »

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance
Healthcare Shares

Own Medibank shares? Here’s what to watch over the coming months

What are the key dates for Medibank in 2022?

Read more »